What Drotaverine-Grindeks Treats: Main Uses and Benefits

Drotaverine-Grindeks is an antispasmodic agent, meaning it is commonly used across therapeutic domains where additional symptomatic support is needed to help with symptoms related to physical discomfort. It is generally applied in addressing symptom clusters related to inflammatory or irritative states and symptoms of increased neurological or muscular activity, particularly those associated with genitourinary and gastrointestinal disorders.

Drotaverine is considered relevant for easing symptoms of increased neurological or muscular activity associated with conditions where symptoms may intensify temporarily, such as in biliary tract disorders, urinary tract disorders, gastrointestinal disorders (as adjuvant therapy), and gynaecological diseases. The medicine is utilized during phases when these symptoms become more noticeable.

In general use, it provides supportive relief when symptoms interfere with routine activities. It assists with maintaining functional stability and contributes to easing the overall symptom burden. One clinical context often described is:

“relevant when supportive symptom management is appropriate.”

---

Quick Fact: Supports symptoms related to physical discomfort

Who Can and Cannot Use Drotaverine-Grindeks – Official Regulatory Information

The eligibility for Drotaverine-Grindeks is strictly defined by official regulatory labeling, which outlines the populations and conditions where use is contraindicated (prohibited) or not recommended.

Absolute Contraindications (Must Not Use)

Use of this medicine is contraindicated (prohibited) for patients with:

• Hypersensitivity (allergy) to Drotaverine or any of the product's excipients.
• Severe Organ Failure: Severe cardiac insufficiency ( severe heart failure), severe hepatic insufficiency (liver), or severe renal insufficiency (kidney).
• Severe Cardiac Conditions: Atrioventricular (AV) blockade II or III grades and cardiogenic shock.
• Specific Comorbidities: Blood disorder known as Porphyria.

Age and Physiological Restrictions

Population Group	Official Eligibility Status
Adults/Adolescents (Typically >12 years)	Established use, subject to contraindications.
Children (<12 years)	Use is generally not recommended or contraindicated in children under 12 years (some regions define specific age cut-offs, such as under 6 years).
Pregnancy	Use is not recommended. Caution is advised.
Lactation (Breastfeeding)	Not recommended due to lack of data on excretion into breast milk.

Conditional Use (Special Caution Required)

Special caution is advised by regulators when the medicine is administered to older adults or to patients with arterial hypotension (low blood pressure), as well as those with non-severe dysfunction of the liver, kidneys, or heart.

Interactions with other medicines and products

This section outlines interactions with other medicinal products and substances as explicitly stated in authoritative government regulatory documents.

---

Documented Pharmacodynamic Interactions

Drotaverine is documented to modify the pharmacological effects of certain co-administered medicines, primarily through pharmacodynamic mechanisms, which affect the functional outcome of the combination:

Interacting Agent	Official Interaction Statement
Levodopa (Anti-Parkinsonian)	Decreases the anti-Parkinsonian effect, potentially leading to an increase in rigidity and tremor.
Other Spasmolytics	The spasmolytic effect is enhanced when co-administered.
Antihypertensives / Vasodilators (e.g., Tricyclic Antidepressants, Riociguat, Quinidine, Procainamide, Isosorbide Mononitrate)	Intensifies the hypotensive and vasodilatory activities.
Morphine (Opioid analgesic)	Reduces the spasmogenic activity of morphine.
Patent Blue (Diagnostic Dye)	The therapeutic efficacy of Drotaverine may be lowered.

---

Restrictions and Limitations

No combinations are formally classified as contraindicated due exclusively to an interaction risk. Official labeling contains no explicit instructions regarding timing separation of doses. Furthermore, no specific interaction-related restrictions are officially documented for food, alcohol, herbal products, or supplements. No population-specific interaction considerations (e.g., heightened severity in hepatic impairment) are stated in the interaction sections of the official labels.

How Drotaverine-Grindeks Works

Drotaverine-Grindeks acts primarily through selective inhibition of the enzyme phosphodiesterase type 4 (PDE4), a molecule with high concentration in smooth muscle cells. This interaction prevents the hydrolysis of cyclic adenosine monophosphate (cAMP) to AMP, leading to an accumulation of intracellular cAMP. The elevated cAMP levels subsequently activate protein kinase A (PKA).

PKA mediates a cascade of phosphorylation events, notably decreasing the activity of myosin light chain kinase (MLCK). Reduced MLCK activity results in a corresponding reduction in the phosphorylation of the myosin light chain (MLC), thereby decreasing the smooth muscle cell's force generation capacity.

Additionally, increased cAMP levels may contribute to a reduction in the concentration of free intracellular calcium ions ( Ca^2+) by promoting the reuptake of Ca^2+ into the sarcoplasmic reticulum. This dual biochemical action, focused on cAMP metabolism and Ca^2+ modulation, is the foundation for promoting smooth muscle relaxation.

Official Administration Guidelines

Drotaverine-Grindeks is used via two primary methods: the oral route, utilizing 40 mg or 80 mg tablets, and the parenteral route, employing a 20 mg/mL solution for injection (intramuscular or intravenous). The specific route employed is determined by clinical necessity, with parenteral administration generally requiring supervision within a clinical setting.

Dosing and Frequency

The standard adult regimen for oral administration involves a total daily dose that ranges from 120 mg to 240 mg. This quantity is typically divided and administered across two or three separate intakes throughout the day. For intravenous use, administration is required to be performed slowly and strictly under the observation of a healthcare professional.

Population-Specific Use

Dosing maximums are established for pediatric patients. For children between 6 and 12 years of age, the maximum total daily dose is 80 mg, divided into two separate administrations. Children over the age of 12 years have a maximum total daily dose of 160 mg, which is distributed across two to four individual doses.

Administration Rules

Tablets are generally swallowed with a full glass of water. The medication does not have a specific requirement to be taken in relation to food intake. If a scheduled dose is missed, it is recommended to take the forgotten dose when remembered, provided it is not near the time for the next scheduled dose; a double dose must not be taken to compensate for the skipped one. These instructions define a standardized protocol that is applied across the forms of the medicine.

Research evidence / Overview of studies for Drotaverine-Grindeks

---

Evidence for Research on Acute Renal Colic

This section summarizes the design of the short-term randomized controlled trials and comparative studies that have evaluated the agent in studies involving adults presenting with acute pain related to kidney or ureteric stones, focusing on the outcomes that researchers measured.

Research has explored the use of this medicine in adults presenting with acute episodes of pain, known as renal colic. Studies were designed as short-term Randomized Controlled Trials (RCTs) and primarily focused on measuring changes in patient-reported pain intensity scores shortly after administration, as well as the need for additional pain relief medication.

Findings describe the patterns of symptom measurement tracked in the study populations during the hours immediately following administration. The results apply primarily to the management of the acute, temporary pain episode. Comparative evidence is sometimes lacking, as some studies used other active medications as the main comparison point.

---

Evidence for Research on Irritable Bowel Syndrome (IBS) Symptoms

Research for IBS has used Randomized, Double-Blind, Placebo-Controlled Trials typically lasting two to four weeks. These studies monitored patient-reported outcomes describing perceived discomfort, primarily tracking the frequency and severity of abdominal pain, as well as changes in stool consistency.

Studies reported on the measurement of abdominal pain scores monitored in patients during the study period. Findings from systematic reviews indicate that research highlights changes measured during the study period, although the consistency of symptom relief across all trials has sometimes been noted to vary.

Some authoritative systematic reviews have noted limitations in the quality of the available data within the evidence base. There is limited information for long-term outcomes or how the perceived effects might be maintained after the treatment period has ended.

---

Evidence for Research on Primary Dysmenorrhea and Labor Augmentation

Studies on Primary Dysmenorrhea

Research has explored the agent in studies involving women presenting with painful menstruation. These involved short-term randomized trials comparing the agent against other pain relief options. Research examined outcomes related to physical discomfort, specifically measuring changes in pain intensity over a few hours following the administration. Some studies were designed to evaluate this agent as part of a combination treatment.

Studies in Relation to Labor Augmentation

In obstetrics, studies monitored the use of this medicine in primigravidas (women pregnant for the first time) in the active phase of uncomplicated labor at term. The primary outcomes tracked were obstetric measures, such as the rate of cervical opening and the overall duration of the first stage of labor. Research provides context regarding the short-term measurement of these defined parameters, but some authoritative bodies have noted that the reported changes in labor duration have not been universally established as clinically significant.

---

Evidence in Specific Populations and Long-Term Outcomes

Studies Involving Pediatric Populations

The evidence base for school-aged children with Recurrent Abdominal Pain (RAP) includes controlled trials that often had small sample sizes. The research monitored outcomes reflecting daily functioning, such as the frequency of pain attacks. The certainty remains low in this population, and some research highlights that key functional outcomes showed mixed findings or no notable change when compared to a placebo.

Duration and Follow-up of Studies

The existing research is split, with studies for acute conditions focusing on acute, short-term responses (hours/days), and trials for conditions like IBS involving intermediate follow-up durations (weeks). Limited information is available for long-term outcomes or the sustainability of responses after treatment is stopped.

Common questions about Drotaverine-Grindeks (FAQ)

---

Q: How long does it take for Drotaverine-Grindeks to start working?

According to official product information, when taken orally, the active ingredient is rapidly and nearly completely absorbed. The maximum concentration in the blood is typically reached within about 45 to 60 minutes. The injectable form, when administered by a healthcare professional, is known to have a faster onset of action.

---

Q: Can Drotaverine-Grindeks be used for labor pain relief?

Official regulatory documents indicate that Drotaverine is used for smooth muscle spasms. However, its use during pregnancy is generally not recommended or requires special caution. Any decision regarding the use of this medicine for labor pain should be discussed with a qualified healthcare professional.

---

Q: What are the possible consequences of taking Drotaverine-Grindeks with Levodopa?

Official labeling documents a specific drug interaction with Levodopa, which is used to treat Parkinson's disease. Taking this combination can decrease the anti-Parkinsonian effect of Levodopa, potentially leading to increased muscle rigidity and tremors. The interaction also carries a risk of increased hypotension (low blood pressure).

---

Q: Can I drink alcohol while taking Drotaverine-Grindeks?

Official drug labeling documents do not typically include a specific restriction regarding the use of alcohol. Since the medicine can cause certain side effects like dizziness and a decrease in blood pressure, for personalized guidance, any concerns regarding alcohol consumption should be discussed with a healthcare professional.

---

Q: What are the active and inactive ingredients in the tablet formulation?

The active substance in this medicine is Drotaverine Hydrochloride. In addition to the active ingredient, the tablet formulation contains various inactive ingredients, known as excipients, which are necessary to form the tablet.

---

Q: Is Drotaverine-Grindeks available over-the-counter or only by prescription?

The availability and status of Drotaverine-Grindeks (whether prescription-only or over-the-counter) are determined by the governing regulatory authority in each specific country. Its regulatory classification can therefore vary internationally.

---

Q: What should I do if I accidentally overdose on Drotaverine-Grindeks?

Official regulatory information warns that an overdose is associated with the risk of cardiac rhythm disturbances and severe conduction disorders, which can potentially lead to cardiac arrest and circulatory collapse. If an overdose is suspected, it is critical to seek immediate emergency medical attention.

---

Q: What is the maximum dose for an adult in a single intake?

Official guidelines provide a standard adult regimen that defines a total daily dose range, typically divided into two or three separate intakes. A healthcare professional is responsible for determining the appropriate single dose amount for an individual, while adhering to the official maximum daily limits.

Storage and Disposal Instructions

Official regulatory documents mandate specific conditions for storing Drotaverine-Grindeks tablets and solution for injection to maintain quality and stability.

Required Storage Conditions

Requirement	Tablet Formulation	Solution for Injection
Temperature	Below 25°C	Below 25°C
Packaging	Store in the original package	Store in the original package
Prohibition	N/A	Do not freeze

Stability and Safety

Both forms must be kept out of the sight and reach of children. The labeled shelf life for the tablets is 3 years, and the injection solution is 5 years, provided the required storage temperatures are maintained.

Disposal

There are no special requirements for the disposal of the unused tablets. However, the injection solution and its waste must not be disposed of via household waste or poured into wastewater. Unused medicine must be discarded according to local environmental requirements.